poisar

Stocks · News reference

Aclarion Has Received A Decision To Grant European Patent Number EP3056919 Titled "MR SPECTROSCOPY SYSTEM AND METHOD FOR DIAGNOSING PAINFUL AND NON-PAINFUL INTERVERTEBRAL DISCS"

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ACON
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  2. Aclarion, Inc.

    Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate Enrollment

    Aclarion announced revised inclusion/exclusion criteria for its CLARITY clinical trial to accelerate patient enrollment. The new criteria, approved at 9 of 11 active sites, better reflect real-world chronic low back pain patients while maintaining scientific rigor. The company expects meaningful enrollment acceleration and will provide an updated timeline for initial readout by year-end, though the overall trial duration remains on track.

    ACONACONW